不同病理类型子宫颈癌中高危型HPV的感染率及归因分析
回顾性分析中国医学科学院肿瘤医院2009年2月至2016年10月收治的1 541例子宫颈癌患者,高危型HPV总感染率为86.6%(1 335/1 541),鳞癌和腺癌是最常见病理类型,鳞癌以HPV 16型为主,腺癌以HPV 18型为主。
要点
- 1 541例子宫颈癌高危型HPV总感染率为86.6%(1 335/1 541)。
- 鳞癌高危型HPV感染率90.1%(1 205/1 337),腺癌为74.7%(65/87)。
- 鳞癌常见致癌亚型为HPV 16型(69.5%),腺癌主要致癌亚型为HPV 18型(44.1%)。
核心结论
- 子宫颈癌主要病理类型为鳞癌和腺癌,鳞癌、腺癌、腺鳞癌、黏液性癌、神经内分泌癌、绒毛状腺癌的发病与高危型HPV感染密切相关。
- 鳞癌主要与HPV 16型感染相关,腺癌主要与HPV 18型感染相关。
研究设计与样本
- 回顾性分析2009年2月至2016年10月在中国医学科学院北京协和医学院肿瘤医院接受治疗的子宫颈癌患者共1 541例,中位年龄49岁(20~82岁)。
- 按地区、诊断年龄和病理类型分析高危型HPV感染率,采用比例归因方法计算13种高危型HPV亚型在不同病理类型中的归因比例。
主要发现
- 1 541例患者高危型HPV总感染率为86.6%(1 335/1 541)。
- 鳞癌≥60岁患者混合感染率23.0%(37/161)高于45~59岁和≤44岁者[分别为11.4%(85/747)、11.7%(50/429),P<0.01],单一感染率68.3%(110/161)低于45~49岁和≤44岁者[分别为77.4%(578/747)、80.4%(345/429),P=0.008]。
- 鳞癌、腺癌、腺鳞癌、黏液性癌、神经内分泌癌、绒毛状腺癌高危型HPV感染率分别为90.1%(1 205/1 337)、74.7%(65/87)、87.0%(20/23)、65.0%(13/20)、72.0%(18/25)和5/5。
- 浆液性癌、内膜样癌、透明细胞癌和微偏腺癌高危型HPV感染率分别为4/9、3/12、2/19和0/4。
- 九价HPV疫苗预防的HPV 16、18、31、33、45、52和58型在鳞癌和腺癌中的归因比例分别为82.6%和68.1%,HPV 45型在鳞癌和腺癌中归因比例仅为0.8%和0。
关键数值与推荐
- 鳞癌常见致癌高危型:HPV 16型(69.5%)、18型(5.6%)、58型(2.2%)、31型(1.9%)、52型(1.4%)、33型(1.3%)。
- 腺癌主要致癌高危型:HPV 18型(44.1%)、16型(20.5%)、52型(2.3%)、58型(1.2%)、51型(1.2%)。
- 腺鳞癌、神经内分泌癌和黏液性癌的主要致癌高危型为HPV 18和16型。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the prevalence of high-risk HPV subtypes in different pathological types of cervical cancer, and analyze the attribution of carcinogenic HPV subtypes in different pathological types. Methods: A total of 1 541 patients with cervical cancer were treated between February 2009 and October 2016 in Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College. The median age at diagnosis was 49 years (ranged 20-82 years old). The numbers of patients with cervical cancer from North China, Northeast China, East China, Central China and other regions (including Northwest, Southwest and South China) were 961, 244, 175, 87 and 74 cases, respectively. Pathological types: 1 337 cases of squamous cell carcinoma (SCC), 87 usual adenocarcinoma (ADC), 23 adenosquamous carcinoma (ASC), 20 mucinous carcinoma (MC), 19 clear cell carcinoma (CCC), 12 endometrioid carcinoma (EC), 25 neuroendocrine carcinoma (NEC), 9 serous carcinoma (SC), 5 villous adenocarcinoma (VADC) and 4 minimal deviation adenocarcinoma (MDAC). The prevalence of high-risk HPV in different regions, age groups at diagnosis and pathological types in cervical cancer were analyzed. The attribution of 13 high-risk HPV subtypes in different pathological types of cervical cancer based on proportional attribution method, and the attribution of high-risk HPV subtypes prevented by 9-valent HPV vaccine in SCC and ADC were calculated. Results: (1) The prevalence of high-risk HPV in 1 541 patients with cervical cancer was 86.6% (1 335/1 541). The multiple high-risk HPV infection rate in patients with SCC ≥60 years old (23.0%, 37/161) was significantly higher than those in patients aged 45-59 years old and ≤44 years old [11.4% (85/747) vs 11.7% (50/429), P<0.01], and the high-risk HPV infection rates of patients with cervical cancer in North China, Northeast China, East China, Central China and other regions were respectively 86.8% (834/961), 87.7% (214/244), 83.4% (146/175), 83.9% (73/87) and 91.9% (68/74). SCC (86.8%, 1 337/1 541) and ADC (5.6%, 87/1 541) were the most common pathological types in cervical cancer. The high-risk HPV prevalence of SCC, ADC, ASC, MC, NEC and VADC were 90.1% (1 205/1 337), 74.7% (65/87), 87.0% (20/23), 65.0% (13/20), 72.0% (18/25) and 5/5 respectively. The high-risk HPV infection rates of SC, EC, CCC and MDAC were 4/9, 3/12, 2/19 and 0/4 respectively. (2) According to proportional attribution, HPV 16 (69.5%), HPV 18 (5.6%), HPV 58 (2.2%), HPV 31 (1.9%), HPV 52 (1.4%) and HPV 33 (1.3%) were the six common high-risk HPV subtypes in SCC. While, HPV 18 (44.1%), HPV 16 (20.5%), HPV 52 (2.3%), HPV 58 (1.2%) and HPV 51 (1.2%) were the main carcinogenic subtypes in ADC. The main carcinogenic high-risk HPV subtypes of ASC, NEC and MC were HPV 18 and HPV 16. The total attribution of HPV 16, 18, 31, 33, 45, 52 and 58 prevented by 9-valent HPV vaccine in SCC and ADC were 82.6% and 68.1% respectively; the attribution of HPV 45 in SCC and ADC were only 0.8% and 0. Conclusions: SCC and ADC are the main pathological types in cervical cancer. SCC, ADC, ASC, MC, NEC and VADC are closely related to high-risk HPV infection. HPV 16 is the main carcinogenic genotypes of SCC. HPV 18 maybe play an important role in the pathogenesis of ADC. 目的: 探讨不同病理类型的子宫颈癌中高危型HPV亚型的感染状况,并对不同病理类型子宫颈癌的致癌HPV亚型进行归因分析。 方法: 2009年2月—2016年10月在中国医学科学院北京协和医学院肿瘤医院接受治疗的子宫颈癌患者共1 541例,其中位年龄为49岁(20~82岁);来自华北、东北、华东、华中和其他地区(包括西北、西南和华南)的患者分别为961、244、175、87和74例;病理类型:鳞癌1 337例、腺癌87例、腺鳞癌23例、黏液性癌20例、透明细胞癌19例、内膜样癌12例、神经内分泌癌25例、浆液性癌9例、绒毛状腺癌5例、微偏腺癌4例。(1)分析不同地区、诊断年龄、病理类型的子宫颈癌患者的高危型HPV感染率;(2)采用比例归因方法计算13种高危型HPV亚型在不同病理类型子宫颈癌中的归因比例,以及九价HPV疫苗预防的高危型HPV亚型在子宫颈鳞癌和腺癌中的归因比例。 结果: (1)1 541例子宫颈癌患者高危型HPV的总感染率为86.6%(1 335/1 541)。1 337例子宫颈鳞癌患者中,≥60岁患者的高危型HPV的单一感染率(68.3%,110/161)明显低于45~49岁和≤44岁者[分别为77.4%(578/747)、80.4%(345/429),P=0.008],但其高危型HPV的混合感染率(23.0%,37/161)明显高于45~59岁和≤44岁者[分别为11.4%(85/747)、11.7%(50/429),P<0.01];华北、东北、华东、华中和其他地区子宫颈癌患者的高危型HPV感染率分别为86.8%(834/961)、87.7%(214/244)、83.4%(146/175)、83.9%(73/87)和91.9%(68/74);子宫颈鳞癌(86.8%,1 337/1 541)和腺癌(5.6%,87/1 541)是子宫颈癌常见的病理类型,子宫颈鳞癌、腺癌、腺鳞癌、黏液性癌、神经内分泌癌、绒毛状腺癌的高危型HPV感染率较高,分别为90.1%(1 205/1 337)、74.7%(65/87)、87.0%(20/23)、65.0%(13/20)、72.0%(18/25)和5/5,但子宫颈浆液性癌、内膜样癌、透明细胞癌和微偏腺癌的高危型HPV感染率较低,分别为4/9、3/12、2/19、0/4。(2)采用比例归因方法计算结果显示,HPV 16型(69.5%)、18型(5.6%)、58型(2.2%)、31型(1.9%)、52型(1.4%)和33型(1.3%)是子宫颈鳞癌常见的6种致癌高危型HPV亚型;HPV 18型(44.1%)、16型(20.5%)、52型(2.3%)、58型(1.2%)和51型(1.2%)是子宫颈腺癌的主要致癌高危型HPV亚型;子宫颈腺鳞癌、神经内分泌癌和黏液性癌的主要致癌高危型HPV亚型为HPV 18和16型。九价HPV疫苗预防的高危型HPV 16、18、31、33、45、52和58型在子宫颈鳞癌和腺癌中的归因比例分别为82.6%和68.1%,其中HPV 45型在鳞癌和腺癌中的归因比例仅为0.8%和0。 结论: 子宫颈癌的主要病理类型为鳞癌和腺癌,子宫颈鳞癌、腺癌、腺鳞癌、黏液性癌、神经内分泌癌、绒毛状腺癌的发病与高危型HPV感染密切相关,其中鳞癌主要与HPV 16型感染相关、腺癌主要与HPV 18型感染相关。.
引用
- Wang WP, An JS, Yao HW, et al. [Prevalence and attribution of high-risk HPV in different histological types of cervical cancer]. Zhonghua Fu Chan Ke Za Zhi. 2019. PMID: 31154709. doi:10.3760/cma.j.issn.0529-567x.2019.05.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。